CTOS 2022 Abstract Submission Requirements

Abstract Title: The abstract title must have a short, specific title (containing no abbreviations) that indicates the nature of the submission. ABSTRACT TITLE MUST BE IN ALL CAPITAL LETTERS. 128 characters (Max 200 characters)/ 18 words (Max 75 words).

Presentation Type: You will be asked to SELECT ONE.
  • Oral
  • Poster
  • Young Investigator: In 1999 the Board of Directors of the Connective Tissue Oncology Society agreed on the institution of the Young Investigator Award. It was decided that this award would be given to two qualified individuals at the Annual Meeting and they would present their paper at the meeting. The criteria for this award is the individual should be less than 35 years of age, still in training or has received their first faculty appointment (instructor, assistant professor or equivalent) on or after July 1 of the previous five years. A letter from the Department Chair or Program Director is required to document eligibility when the candidates submit their abstracts for review. Awardees are notified in September prior to the meeting. Each winner receives a complimentary registration to the meeting as well as an honorarium for $2000 each.

Category: You will be asked to SELECT ONE. Options are here.

Abstract: You will be asked to complete all 4 sections below. We prefer you do not exceed 4,000 characters for the entire abstract, however you can see the maximum for each of the four sections of the abstract listed below. Images and tables (uploaded in a separate section) are not counted in the 4,000 characters.
  Objective: (10 - 2,000 characters)
  Methods: (10 - 2,000 characters)
  Results: (10 - 2,000 characters)
  Conclusion: (10 - 2,000 characters)

Table, Chart or Image: Upload up to 4 tables, chart or images that are to be included with your abstract submission. If you do not have any files to upload, you can opt out.

Author/Co-Author list: You will create a list of authors (limit 30). Your submission must have a 1 person listed as the "Author" who will serve as the main contact for this submission. We recommend this be the person submitting the abstract. All other individuals added will be listed as "Co-Authors." First Name, Last Name, email address, city, state, country, job title, organization, degrees and role are required for each person.

Disclosure Information: The person completing the form is required to submit a Conflict-of-Interest Disclosure by answering the: FDA Disclosure, Manufacturer's Name and Drugs or Devices, and Financial Relationship for the abstract submission. The answers will apply to ALL co-authors listed on the abstract.
2022 CTOS Abstract General Information

Important Dates

April 1  Call for Abstracts

June 27  Abstract Submission Deadline  **NEW DATE!!**

August 15  Abstract Acceptance Notifications

November 16  Abstracts Available for Viewing Online

Embargo Policy

All meeting attendees, members of the media, companies, institutions, organizations, universities, investment advisors, and all other individuals are required to abide by the embargo policy governing the 2022 CTOS Annual Meeting.

An embargo means that information from any abstract or presentation is confidential and may not be announced, publicized, or distributed before the embargo date and time. This policy applies to all formats of release, including the Scientific Sessions online itinerary planner, meeting app and any other distribution method.

The purpose of the embargo policy is to protect the scientific integrity of the abstract submissions presented at the CTOS Annual Meeting. All submissions are to be considered preliminary until the time of presentation or authorized for public release.

Oral and Poster Presentations:
Abstracts selected for oral presentation are embargoed from the time of submission until the commencement of the 2022 CTOS Annual Meeting on November 16th at 9am EST. CTOS reserves the right to adjust the embargo as needed.

CTOS will evaluate exception requests on a case-by-case basis and reserves the right to change the type of presentation (from oral presentation to poster presentation) or remove the abstract from the meeting program if it determines that the released information may substantially detract from the novelty of the presentation.

Questions?? Please email Barbara Rapp at ctos@ctos.org